05:21 PM EDT, 08/26/2024 (MT Newswires) -- BioSyent ( BIOYF ) said Monday afternoon its second-quarter earnings and revenue rose year-over-year as all of its Canadian pharmaceutical brands grew during the quarter.

The company said it earned $1.58 million, or $0.13 share, up 8% from $1.48 million, or $0.12, a year ago. Analysts polled by Capital IQ expected $0.13.

Revenue rose to $8.95 million, up from $7.96 million a year earlier. Analysts surveyed by Capital IQ expected $8.80 million.

The company declared a $0.045 per share dividend to be paid on Sept. 15.

"We are pleased to report our highest-ever quarterly Canadian Pharma sales and Total Company sales for Q2 2024," said Chief Executive Rene Goehrum. The company's total revenue for the first half of the year was $16.68 million, up from $14.45 million in H1 2023.

The company's shares closed down $0.06 to $10.21 on the TSX Venture Exchange.